Sec Form 5 Filing - SCANGOS GEORGE A @ Vir Biotechnology, Inc. - 2021-12-31

FORM 5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SCANGOS GEORGE A 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500 3. Date of Earliest Transaction (MM/DD/YY) 12/31/2021 (Street) SAN FRANCISCO, CA94158 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/16/2021 G V 900,000 D $ 0 3,709,559 D Common Stock 04/01/2021 G V 3,598,559 D $ 0 111,000 D Common Stock 04/01/2021 G V 3,598,559 A $ 0 3,598,559 I See footnote( 1 ) Common Stock 09/07/2021 G V 1,907,329 D $ 0 0 I See footnote( 2 ) Common Stock 09/07/2021 G V 61,660 A $ 0 61,660 I See footnote( 3 ) Common Stock 09/07/2021 G V 877,135 A $ 0 877,135 I See footnote( 4 ) Common Stock 09/07/2021 G V 61,660 A $ 0 61,660 I See footnote( 5 ) Common Stock 09/07/2021 G V 877,135 A $ 0 877,135 I See footnote( 6 ) Common Stock 09/07/2021 G V 29,739 A $ 0 140,739 D Common Stock 115,000 I See footnote( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SCANGOS GEORGE A C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO, CA94158 X President and CEO Signatures /s/ Howard Horn, Attorney-in-Fact 02/14/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. ( 2 )On August 30, 2018, the reporting person contributed 1,907,329 shares of the Issuer's common stock to the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "Trust"), a grantor retained annuity trust for the benefit of himself and his children. Upon termination of the Trust, an aggregate of 1,877,590 of the shares were transferred to trusts for the benefit of each of his daughters, of which he and his spouse serve as trustees. The remaining 29,739 shares were distributed to the reporting person. ( 3 )The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. ( 4 )The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. ( 5 )The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. ( 6 )The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. ( 7 )The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.